T h e ne w e ngl a nd jou r na l o f m e dicine T he malaria parasite can persist and reappear in areas where infection is no longer circulating or is circulating at very low levels. 1 Since prevention of reinfection and resurgence is an integral component of the current goal to eradicate malaria, 2 understanding the determinants and clinical consequences of malaria declines and resurgences, as well as the timescales for gain and loss of antimalarial immunity, has become a priority.
Malaria is an infectious disease that requires boosting to maintain immunity over time 3 ; a reduction in parasite exposure can lead to a loss of population-level immunity and an increase in the harmful effects of malaria infections during resurgences. 4 Because of the increased susceptibility to malaria during pregnancy, 5 the consequences of a reduction in malaria immunity among pregnant women could be particularly severe, especially in the context of the human immunodeficiency virus (HIV) pandemics in Africa, 6 which can impair the maintenance of effective immune responses. 7 However, declining malaria transmission among pregnant women [8] [9] [10] may have an effect on malaria-related clinical outcomes that has not yet been assessed.
In areas where malaria is endemic, antibodies against Plasmodium falciparum VAR2CSA 11 develop in pregnant women. VAR2CSA is a variant surface antigen that mediates placental accumulation of infected erythrocytes 12 and leads to the deleterious effects on the mothers and their offspring, especially in primigravid women. 13 Antibodies against VAR2CSA are acquired after exposure to placental parasites in a parity-dependent manner, 14 contribute to a reduction in the clinical consequences of malaria in pregnancy, 15 and are affected by variables that influence the risk of exposure to P. falciparum. [16] [17] [18] Therefore, decreases in this pregnancy-specific immunity after reductions in transmission might affect the disease burden during resurgences.
Although the relationship between the prevalence of malaria among pregnant women and the prevalence in the general community is still incompletely understood, 19 malaria testing in pregnant women at health care facilities can provide information about the effect of changes in malaria transmission on the disease burden. To better understand the consequences of malaria resurgences, we examined parasitologic, immunologic, and clinical trends among pregnant women delivering between 2003 and 2012 in the Manhiça District in southern Mozambique.
Me thods

Study Sites and Population
Pregnant women who provided written informed consent to participate in two clinical trials of  antimalarial drugs between 2003 and 2005  20 and  between 2010 and 2012 21,22 at antenatal clinics in the Manhiça District were included in the study. Biases due to pooling of data from these two clinical trials, as well as to changes from the earlier to the later period in the health care provided to the women, were minimized by the use of similar protocols and procedures during the two trials. The intensity of malaria transmission in this region used to be moderate 23 and has decreased in the past few years, as evidenced by a reduction in hospital admissions for malaria. The area has been under continuous demographic surveillance by the Centro de Investigação em Saúde da Manhiça (CISM) since 1996. 24 All women included in the study received bed nets treated with long-lasting insecticide, as well as intermittent preventive treatment during pregnancy, which in 2003-2005 consisted of two doses of sulfadoxine-pyrimethamine 20 and in 2010-2012 consisted of two doses of mefloquine or sulfadoxine-pyrimethamine, if the women were HIV-negative, 22 or three doses of mefloquine or placebo, if they were HIV-positive and were receiving trimethoprim-sulfamethoxazole prophylaxis. 21 At delivery, maternal hemoglobin was measured with the use of a HemoCue or Sysmex KX21 analyzer, and newborns were weighed (with the use of weekly calibrated scales, which were either digital scales 20 or triple-beam balances 21, 22 ). Tissue samples from the maternal side of the placenta, as well as 50 μl of maternal peripheral-, placental-, and cord-blood samples on filter papers, were collected for parasitologic assessments. At delivery, peripheral blood was collected into EDTA vacutainers and centrifuged, with the plasma stored at −20°C. Clinical malaria episodes were treated according to national guidelines at the time of the study, and parenteral quinine was administered for severe malaria. The study protocols and informed-consent forms were reviewed and approved by the National Ethics Review Committee of Mozambique and the Ethics Review Committee of the Hospital Clinic of Barcelona.
Thick and thin blood films, as well as placentalbiopsy samples in 10% neutral buffered formalin, were assessed for detection of plasmodium species according to standard, quality-controlled procedures. [25] [26] [27] A random selection of 50% of the peripheral-blood samples (958 samples) and placental-blood samples (941) on filter papers was used for detection of P. falciparum in duplicate by means of a real-time quantitative polymerasechain-reaction (qPCR) assay targeting 18S ribosomal RNA (rRNA) 28 (see the Methods section in the Supplementary Appendix, available with the full text of this article at NEJM.org).
Measurement of Antimalarial IgG Antibodies
A random selection of 35% of the peripheralblood plasma samples (654 samples) collected at delivery was used for flow-cytometric measurement of IgG 16 (expressed as mean fluorescence intensity [MFI]) against a chondroitin sulfate A-binding parasite line expressing VAR2CSA (CS2), indicating pregnancy-specific antimalarial immunity, 29 and a rosetting parasite line (R29), indicating general antimalarial immunity 30 (see the Methods section in the Supplementary Appendix). The P. falciparum CS2 (MRA-96) laboratory strain was obtained through the Malaria Research and Reference Reagent Resource Center (MR4) as part of the BEI Resources Repository, National Institute of Allergy and Infectious Diseases, National Institutes of Health.
Study Definitions
Pregnant women were included in the analysis if they received sulfadoxine-pyrimethamine, mefloquine, or trimethoprim-sulfamethoxazole, alone or in combination with mefloquine, during pregnancy and if all information was available on the date of delivery, HIV status, age, and parity, as well as results of peripheral-blood microscopic examination and placental histologic assessment. Women were classified a priori as primigravid (first pregnancy) or multigravid (at least one previous pregnancy), and age was categorized as younger than 20 years, 20 to 24 years, or 25 years of age or older. 16, 17 Maternal microscopic infection at delivery was defined as the presence of P. falciparum parasites in peripheral blood or in the placenta on either microscopic or histologic examination, qPCR-positive infection was defined as a positive result of qPCR testing in peripheral or placental blood, and submicroscopic infection was defined as the presence of malaria parasites on qPCR testing but not on microscopic examination. Past placental infection was defined by the presence of malaria pigment (i.e., hemozoin 27 ) without parasite detection on placental histologic examination, and chronic placental infection was defined by the presence of malaria pigment in combination with the detection of parasites.
Statistical Analysis
Our primary hypothesis was that declines in the prevalence of malaria would be associated with reductions in antimalarial immunity, and our secondary hypothesis was that reduced immunity would lead to higher parasite densities, smaller differences in parasite densities and antibody levels between primigravid and multigravid women, and a larger adverse effect of malaria. Proportions were compared by means of Fisher's exact test, and continuous variables by means of Student's t-test. The primary outcome variables -maternal microscopic infection and level of IgG antibodies against CS2 -were compared between the two study periods we used linear regression to analyze the effect of study period on log-transformed parasite densities, as well as the effect of malaria on maternal hemoglobin levels and newborn weight in each of the two periods. To determine whether a modification of the associations with parity was attributable to the study period, we included an interaction term in the regression models and assessed separately the effect of parity for each period. The data were analyzed with the use of Stata software, version 11.0 (Stata). P values of less than 0.05 were considered to indicate statistical significance for primary outcomes, with Bonfer- roni corrections applied for the secondary outcome variables tested.
R esult s
Study Population
A total of 2259 women received bed nets treated with long-lasting insecticide and were given prophylaxis with sulfadoxine-pyrimethamine, mefloquine, or trimethoprim-sulfamethoxazole, alone or in combination with mefloquine, in the context of the two clinical trials of intermittent preventive treatment of malaria in pregnancy that were conducted in Manhiça. [20] [21] [22] Of these women, 440 were excluded because of missing data on HIV status, peripheral-blood microscopic examination, or placental histologic examination ( Fig. S1 and Table S1 in the Supplementary Appendix). The 1819 women included in this study delivered between October 27, 2003, and August 14, 2012, and were similar in terms of baseline characteristics with all 2259 women participating in the randomized trials (Table S1 in the Supplementary Appendix), as were women in both study periods (Table 1) .
Trends in Malaria during Pregnancy
The prevalence of maternal microscopic infection at delivery (primary outcome) decreased from 11% in 2003-2005 to 2% in 2010-2012 (Table 1) (adjusted odds ratio, 0.19; 95% confidence interval [CI], 0.12 to 0.30; P<0.001). Similar decreases were observed in secondary parasitologic outcomes (P<0.001 in all cases) ( Table 1) . Microscopic examination of peripheral blood and histologic examination of the placenta, as compared with qPCR testing, are described in Table S2 Secondary analysis by year showed that the prevalence of microscopic maternal infection decreased from 12% in 2003-2004 to 1% in 2010 (P<0.001, adjusted), and the prevalence of qPCRpositive maternal infection decreased from 33% to 2% (P<0.001, adjusted), with increases in 2012 to 4% for microscopic infections (P = 0.003, adjusted) and to 6% for qPCR-positive infections (P = 0.03, adjusted) ( Fig. 1, and Fig. S2 in the Supplementary Appendix). Similar trends were observed after the exclusion of women who received mefloquine as intermittent preventive treatment of malaria during pregnancy in the 2010-2012 period (Table S3 in the Supplementary Appendix). Cord-blood microscopic infections were consistently low (≤1%) throughout the study period.
Antimalarial Immunity
Geometric mean levels of IgG against CS2 (primary outcome) were lower in 2010-2012 than in [2003] [2004] [2005] (Table 1) (Abbott Laboratories) and was confirmed by means of the Uni-Gold HIV Rapid Test (Trinity Biotech). § CD4+ T-cell counts were performed in BD Trucount tubes (BD Biosciences). ¶ The P value is significant according to multivariate analysis adjusted for HIV status, parity, and age. ‖ Maternal microscopic infection was defined by the presence of P. falciparum parasites in peripheral blood or in the placenta on microscopic or histologic examination, respectively. ** MFI (mean fluorescence intensity) was measured in arbitrary fluorescence units. † † Maternal qPCR-positive infection was defined by a positive result on qPCR testing in peripheral or placental blood. The relationship of parity to parasite density, submicroscopic infections, and IgG levels differed between the two study periods. In the 2003-2005 period, higher parity was associated with a decrease in parasite densities in peripheral blood on microscopic examination and qPCR testing, as well as in placental blood on qPCR testing (Table 2 ). In contrast, parasite densities were similar between primigravid and multigravid women in the 2010-2012 period. Results are shown for microscopic assessment of peripheral blood (Panel A), histologic assessment of the placenta (Panel B; lower limit of quantification, ≤1%), and qPCR testing of peripheral and placental blood (Panels C and D, respectively). For Panels C and D, the lower limit of quantification was 2 genomes per microliter, which was the number assigned if qPCR amplification was observed outside the lower range of the standard curve (i.e., 5 genomes per microliter). I bars represent geometric means plus 95% confidence intervals. P values are based on a multivariate analysis adjusted for HIV status, parity, and age. to 4% on the basis of qPCR assay) were paralleled by reductions in levels of antimalarial IgG antibodies. These changes over a 10-year period were associated with increasing parasite densities and a larger adverse effect of infection on maternal hemoglobin levels and on the weight of newborns during the period of low malaria prevalence. Taken together, the data suggest that a weakening of antimalarial immunity as a result of infrequent parasite exposure can increase the occurrence of high-density infections and their harmful effect among women who become infected, as well as among their newborns. The decline in the prevalence of malaria between 2003 and 2010, which was associated with a slight increase in the mean maternal hemoglobin level, is consistent with reductions in other areas of sub-Saharan Africa over similar time frames, 9,10,31,32 suggesting a continent-wide trend during this period. Intermittent preventive treatment with mefloquine during pregnancy in a number of the women between 2010 and 2012 was not responsible for the decrease in the prevalence of malaria, since similar declines were observed when these women were excluded from the analysis. Also, the numbers of malariasusceptible primigravid women, rates of HIV infection, and CD4+ T-cell counts in HIV-infected women were relatively constant throughout the study period, and all the women received bed nets treated with a long-lasting insecticide, suggesting that these factors do not fully account for the changes observed. The introduction of artemisinin-based combination therapies in Mozambique in 2009, together with increasing use of intermittent preventive treatment with sulfadoxine-pyrimethamine during pregnancy and insecticide-treated bed nets, as recommended by the World Health Organization in 2005, may have contributed to the observed decline in the prevalence of malaria, together with socioeconomic development, improved accessibility to health care facilities, and continuous conduct of clinical trials and other investigations in the study area. The increases in prevalence between 2010 and 2012 without evident changes in malariacontrol efforts suggest that climate factors, as well as increasing mosquito and parasite resistance to insecticides and antimalarial agents, respectively, may have played a role. Although similar trends have been observed in malariarelated hospital admissions in the area, 33 it remains unclear whether health care facility-based trends in malaria among pregnant women who are targets of intensive preventive measures can be extrapolated to the general community.
Levels of IgG antibodies against CS2 parasites (pregnancy-specific immunity) and R29 parasites (general immunity) mirrored changes in the prevalence of malaria infection. Moreover, levels of IgG antibodies against CS2 were increased in women with qPCR-positive P. falciparum infection at delivery. 16, 17 These results indicate a close relationship between antibody levels and the intensity of malaria transmission [16] [17] [18] [34] [35] [36] and suggest that antibodies against VAR2CSA may be a marker for cumulative exposure to the parasite during pregnancy. 19 More important, this study shows that 5 years of a marked decline in the prevalence of malaria was accompanied by reductions in levels of IgG antibodies against CS2 parasites by a factor of 2.8 and by reductions in IgG antibodies against antigens that are not specific to pregnancy, as well as by an increase in the geometric mean of parasite densities and a larger adverse effect of these infections on maternal hemoglobin levels and the weight of newborns. Reduced opportunities to acquire immunity during pregnancy because of low infection rates may render multigravid women as susceptible to malaria as primigravid women, as suggested by the similar parasite densities and levels of IgG antibodies against CS2 in the two groups of women during the period of low malaria prevalence. In accordance with previous reports on pregnant women 9 and children 37, 38 residing in areas where malaria has declined substantially, these observations suggest that infrequent parasite exposure can weaken immune regulation of parasite density and increase the occurrence of adverse clinical outcomes among women who become infected, as well as among their newborns. However, the increase in antibody levels between 2010 and 2012 after relatively modest increments in the prevalence of infection suggests that immunity may be regained as exposure increases. Copyright © 2015 Massachusetts Medical Society. All rights reserved.
T h e ne w e ngl a nd jou r na l o f m e dicine Our study has several limitations. Although similar procedures were followed in both study periods, possible confounding factors, such as changes in health care (i.e., access to antiretroviral agents and prenatal care) and in other vectorborne infections, were not measured, and we did not control for pooling of data from separate cohorts in this study. Moreover, estimates of the prevalence of malaria among women undergoing malaria-prevention measures at the hospital may not be representative of the prevalence in the community at large.
In conclusion, this study shows a rise in malaria with increased parasite densities and a larger adverse clinical effect after a marked fall in the prevalence of malaria and antimalarial immunity among pregnant women. These data reinforce the importance of sustaining efforts to avoid rebounds of malaria associated with reductions in naturally acquired immunity.
